105 related articles for article (PubMed ID: 26881321)
21. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M
Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469
[TBL] [Abstract][Full Text] [Related]
22. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
[TBL] [Abstract][Full Text] [Related]
23. Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer.
Juhász E; Kim JH; Klingelschmitt G; Walzer S
Eur J Cancer; 2013 Apr; 49(6):1205-15. PubMed ID: 23477998
[TBL] [Abstract][Full Text] [Related]
24. Molecular testing in lung cancer: fine-needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication.
Rafael OC; Aziz M; Raftopoulos H; Vele OE; Xu W; Sugrue C
Cancer Cytopathol; 2014 Jun; 122(6):454-8. PubMed ID: 24723383
[TBL] [Abstract][Full Text] [Related]
25. An Evaluation of Algorithms for Identifying Metastatic Breast, Lung, or Colorectal Cancer in Administrative Claims Data.
Whyte JL; Engel-Nitz NM; Teitelbaum A; Gomez Rey G; Kallich JD
Med Care; 2015 Jul; 53(7):e49-57. PubMed ID: 23524464
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer.
He YY; Zhang XC; Yang JJ; Niu FY; Zeng Z; Yan HH; Xu CR; Guan JL; Zhong WZ; Yang LL; Guo LH; Wu YL
Clin Lung Cancer; 2014 Nov; 15(6):441-7. PubMed ID: 25044104
[TBL] [Abstract][Full Text] [Related]
27. Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?
Choi YW; Ahn MS; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Lee SY
Lung Cancer; 2015 Feb; 87(2):155-61. PubMed ID: 25488862
[TBL] [Abstract][Full Text] [Related]
28. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
Trials; 2015 Apr; 16():146. PubMed ID: 25873045
[TBL] [Abstract][Full Text] [Related]
29. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
30. Preselection based on clinical characteristics in German non-small-cell lung cancer patients screened for EML4-ALK translocation.
Tufman AL; Edelmann M; Gamarra F; Reu S; Borgmeier A; Schrödl K; Zauber R; Müller-Lisse U; Huber RM
J Thorac Oncol; 2014 Jan; 9(1):109-13. PubMed ID: 24346098
[TBL] [Abstract][Full Text] [Related]
31. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE
Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084
[TBL] [Abstract][Full Text] [Related]
32. Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care system.
Ellis PM; Verma S; Sehdev S; Younus J; Leighl NB
J Thorac Oncol; 2013 Sep; 8(9):1136-41. PubMed ID: 23887170
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea.
Baek JH; Sun JM; Min YJ; Cho EK; Cho BC; Kim JH; Ahn MJ; Park K
Lung Cancer; 2015 Feb; 87(2):148-54. PubMed ID: 25498243
[TBL] [Abstract][Full Text] [Related]
34. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
35. p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients.
Murakami I; Hiyama K; Ishioka S; Yamakido M; Kasagi F; Yokosaki Y
Clin Cancer Res; 2000 Feb; 6(2):526-30. PubMed ID: 10690534
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
Ichihara E; Hotta K; Nogami N; Kuyama S; Kishino D; Fujii M; Kozuki T; Tabata M; Harada D; Chikamori K; Aoe K; Ueoka H; Hosokawa S; Bessho A; Hisamoto-Sato A; Kubo T; Oze I; Takigawa N; Tanimoto M; Kiura K
J Thorac Oncol; 2015 Mar; 10(3):486-91. PubMed ID: 25695221
[TBL] [Abstract][Full Text] [Related]
37. Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox".
Arrieta O; Ramírez-Tirado LA; Báez-Saldaña R; Peña-Curiel O; Soca-Chafre G; Macedo-Perez EO
Lung Cancer; 2015 Nov; 90(2):161-6. PubMed ID: 26358312
[TBL] [Abstract][Full Text] [Related]
38. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
Lee VH; Leung DK; Choy TS; Lam KO; Lam PM; Leung TW; Kwong DL
BMC Cancer; 2016 Feb; 16():147. PubMed ID: 26911310
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
